Semaglutide and walking capacity in symptomatic PAD and type 2 diabetes patients: the STRIDE trial Selected in The Lancet by Xavier Devoisin This phase 3b, double-blind, randomised, placebo-controlled trial assessed the effect of semaglutide on walking capacity in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes
This is normal and typically resolves within minutes
While OEA might support weight management, its not a one-to-one swap for something like Ozempic or Mounjaro
The Precision Peptide Genetic Test ($298) analyzes 14 metabolic pathways, 49 peptides, and 150+ genetic insights including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313
In these types of situations, gradually tapering off the drug may be better in order to assess for any recurrent blood sugar elevation or weight regain
If you are experiencing severe vomiting or diarrhea from the flu, your healthcare provider may suggest delaying your dose to prevent severe dehydration